CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) had Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year of -$6.34 million as of 2019-12-28, per its 10-K filed 2020-02-11.
Discontinued › Notes › Compensation Related Costs › Defined Benefit Plan › Defined Benefit Plan, Expected Amortization, Next Fiscal Year
us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear · last filed 2020-02-11
- 2019-12-28: Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year -$6.34M.
- 2018-12-29: Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year -$1.95M.
- 2017-12-30: Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year -$3.01M.
| Period end | Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year |
|---|---|
| 2019-12-28 | -$6.34M 10-K · filed 2020-02-11 |
| 2018-12-29 | -$1.95M 10-K · filed 2019-02-13 |
| 2017-12-30 | -$3.01M 10-K · filed 2018-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |